Deutsche Bank Sticks to Their Hold Rating for AstraZeneca (AZN)
Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of ...
Drugmaker Biogen Forecasts 2025 Profit Below Expectations
On an adjusted basis, Biogen expects 2025 profit between $15.25 and $16.25 per share. It earned $16.47 in 2024 and analysts ...
J.P. Morgan Reaffirms Their Hold Rating on Bayer (0P6S)
J.P. Morgan analyst Richard Vosser maintained a Hold rating on Bayer (0P6S – Research Report) today and set a price target of €25.00. The ...
Kidney Transplant Rejection Market To Observe Growth At A CAGR Of 4.9% During The Forecast Period (2024-2034) Delveinsight
The kidney transplant rejection prophylaxis market is projected to experience steady growth, driven by the introduction of innovative therapi ...
Biogen (BIIB) Q4 2024 Earnings Call Transcript
At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. [Operator instructions] Today's conference is being recorded. Thank you. I ...